Vaccine Development

Tumor Necrosis Factor - alpha (TNFa) inhibiting compound as a first in class drug treatment for neuroinflammatory diseases. Know More...

Whats New

Delivery System

Optimization and scale-up of developed transdermal delivery system for Rheumatoid Arthritis.
Know More...

Hospital Central

Herbal Adjuvant

To evaluate the toxicological properties of the novel herbal adjuvant.
Know More...

Clinic Central

Point of Care Device

Point of care device as decision making tool in severe Traumatic Brain Injury (sTBI) Patients.Know More...

My Health Central
Next
Prev

The Company

Yasham P2D Life Sciences (YP2DLS) has a research development business model that is an amalgamation of precision and practical application targeted towards unmet medical needs in India and other developing markets...

Know More...

Projects

  • Tumor Necrosis Factor - alpha (TNFa) inhibiting compound as a first in class drug treatment for neuroinflammatory
  • Optimization and scale-up of developed transdermal delivery system for Rheumatoid
Know More...

Target Areas

  • Traumatic Brain Injury
  • Alzheimer's
  • Parkinson's
  • Vaccine development
  • Biomarkers and biologics
  • Point of Care
  • Infectious Disease
Know More...

Contact Us

Telephone :
+91-22- 40639900
Fax :
+91-22- 40639901
Email:
smaroliya@yasham.in gskulkarni@yasham.in

Know More...